Bristol-Myers Squibb announced the submission of a new drug application to Japan’s Pharmaceutical and Medical Devices Agency seeking the world’s first interferon-free and ribavirin-free treatment regimen for patients with chronic hepatitis C.
Bristol-Meyers Squibb